NextCell Pharma files patent application
NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company’s proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans.The selection algorithm is based on multiple functional assays used to identify and select cells and donors withspecified desired characteristics. ProTrans is a pooled allogeneic stem cell product, consisting of cells from multipledonors. The pooling process supports the production of large batches. The combination